Blog

Drugmakers see a pricing blueprint in an $850000 gene therapy – Reuters

Drugmakers see a pricing blueprint in an $850000 gene therapy
Reuters
SAN FRANCISCO (Reuters) – Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. Spark Therapeutics Inc plans to launch its

and more »

2018-01-12 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.